Last €3.06 EUR
Change Today -0.019 / -0.62%
Volume 0.0
YDO On Other Exchanges
Symbol
Exchange
NASDAQ GM
Stuttgart
As of 12:24 PM 04/23/14 All times are local (Market data is delayed by at least 15 minutes).

synta pharmaceuticals corp (YDO) Snapshot

Open
€3.15
Previous Close
€3.08
Day High
€3.15
Day Low
€3.02
52 Week High
04/23/13 - €7.86
52 Week Low
11/14/13 - €2.71
Market Cap
280.3M
Average Volume 10 Days
57.1
EPS TTM
--
Shares Outstanding
91.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for SYNTA PHARMACEUTICALS CORP (YDO)

synta pharmaceuticals corp (YDO) Related Businessweek News

No Related Businessweek News Found

synta pharmaceuticals corp (YDO) Details

Synta Pharmaceuticals Corp., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs for treating severe medical conditions, including cancer and chronic inflammatory diseases. The company has two drug candidates in clinical trials for treating multiple types of cancer and various drug candidates in the preclinical stage of development. Its lead drug candidate includes ganetespib, an Hsp90 inhibitor, which is in Phase III clinical trial for the treatment of non-small cell lung cancer; in Phase II clinical trial for patients with hormone receptor positive metastatic breast cancer; in Phase I clinical trial for the treatment of HER2 positive patients with metastatic breast cancer; in Phase II/III clinical trial for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome; and in Phase I/II trial of paclitaxel in combination with ganetespib in patients with platinum-resistant ovarian cancer. The company’s product pipeline also comprises Hsp90-inhibitor Drug Conjugate, a novel, proprietary small molecule cancer drug development program; and Elesclomol, a mitochondria-targeting agent that is in Phase 2 clinical trial for ovarian cancer. Its product pipeline in preclinical development stage for inflammatory diseases includes CRACM ion channel inhibitors for rheumatoid arthritis, asthma, chronic obstructive pulmonary disease, allergy, transplant rejection, and other autoimmune diseases and inflammatory conditions; and IL-12/23 inhibitors for inflammatory and autoimmune diseases. Synta Pharmaceuticals Corp. was incorporated in 2000 and is based in Lexington, Massachusetts.

134 Employees
Last Reported Date: 03/11/14
Founded in 2000

synta pharmaceuticals corp (YDO) Top Compensated Officers

Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $355.8K
Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: $501.5K
Vice President of Intellectual Property & Leg...
Total Annual Compensation: $353.6K
Compensation as of Fiscal Year 2012.

synta pharmaceuticals corp (YDO) Key Developments

Synta Pharmaceuticals Corp. Announces Positive Interim Results from the ENCHANT-1 Trial of Ganetespib in Metastatic Breast Cancer Conference

Synta Pharmaceuticals Corp. announced presentation of interim results from the ENCHANT-1 trial, a single-arm multi-center Phase 2 proof-of-concept study designed to evaluate ganetespib, the company's lead drug candidate, administered as monotherapy for the treatment of metastatic breast cancer. The ENCHANT-1 trial was designed to evaluate ganetespib single agent activity in metastatic breast cancer and identify potential predictive biomarkers. Target enrollment is 35 patients in three cohorts, which include HER2+ breast cancer, triple-negative breast cancer (TNBC), and, recently added and now recruiting, ER/PR-positive patients previously untreated for locally advanced or metastatic disease. The goal of the trial design is to obtain initial evidence of a clinical activity signal with single-agent ganetespib administered for up to 12 weeks. Continuation of ganetespib as a single agent or in combination with paclitaxel after the initial assessment is at investigator discretion. To date, 10 patients were enrolled into the HER2+ cohort and 38 patients were enrolled into the TNBC cohort. Of the patients evaluable for metabolic response based on having reached the week 3 PET assessment, 6 of 7 achieved a metabolic response in the HER2+ cohort and 18 of 31 achieved a metabolic response in the TNBC cohort. Of the 6 HER2+ and 26 TNBC patients that reached the 6 week assessment and therefore evaluable for objective RECIST response, 4 achieved an objective response (CR+PR) and two achieved stable disease (SD) in the HER2+ cohort, while 2 achieved an objective response, 11 achieved stable disease, and 13 had progressive disease in the TNBC cohort. All objective responses were confirmed by independent radiological review. Of note, one HER2+ patient achieved a complete objective response and has remained on treatment for over 10 months. Consistent with previously reported results, diarrhea, fatigue, and nausea were the most common adverse events associated with ganetespib treatment, and were mostly Grade 1 or 2 in severity.

Synta Pharmaceuticals Corp. Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2013

Synta Pharmaceuticals Corp. reported unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2013. For the quarter, there were no revenues recognized. The company reported a net loss of $24.2 million or $0.31 per basic and diluted loss per share compared to a net loss of $18.1 million or $0.29 per basic and diluted loss per share for the same period in 2012. Loss from operations was $24.444 million against $17.703 million for the same period a year ago. For the full year, there were no revenues recognized. The company reported a net loss of $90.2 million or $1.27 per basic and diluted loss per share compared to a net loss of $62.8 million or $1.06 per basic and diluted loss per share for the same period in 2012. Loss from operations was $87.559 million against $60.941 million for the same period a year ago.

Synta Pharmaceuticals Corp. Announces Management Changes

Synta Pharmaceuticals Corp. announced that Safi R. Bahcall, Ph.D., has resigned as President, Chief Executive Officer and a member of the Board of Directors, effective immediately, and has been replaced by a newly formed Executive Committee of the Board. The Committee will be chaired by Keith R. Gollust, the company's Chairman of the Board of Directors, and include current Director Robert N. Wilson, retired Vice Chairman of Johnson & Johnson, and newly appointed Director Paul A. Friedman, M.D., the former Chief Executive Officer of Incyte Corporation. The committee will serve as the principal executive body for the company until such time as a Chief Executive Officer is named. Dr. Friedman's appointment to the Board of Directors is also effective immediately. He was Chief Executive Officer of Incyte Corporation from 2001 until his retirement in January 2014. He continues to serve as a director of Incyte as well as Auxilium Pharmaceuticals, Durata Therapeutics, and two privately held companies.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
YDO:GR €3.06 EUR -0.019

YDO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for YDO.
View Industry Companies
 

Industry Analysis

YDO

Industry Average

Valuation YDO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 7.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SYNTA PHARMACEUTICALS CORP, please visit www.syntapharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.